FrancophonIA/ELRC3.0 huggingface dataset:
English: During its February 2007 meeting, the CHMP, in the light of the overall submitted data and the scientific discussion within the Committee, was of the opinion that the proposal for the harmonisation of the SPC, Labelling and Package leaflet was acceptable and that they should be amended.
Slovenian: Na seji februarja 2007 se je CHMP na osnovi vseh predloženih podatkov in znanstvene razprave v odboru odločil, da je predlog za uskladitev Povzetka glavnih značilnosti zdravila, označevanja in Navodila za uporabo sprejemljiv in da bi jih bilo treba dopolniti.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II together with the amended SPC, labelling and package leaflet in Annex III.
Slovenian: Seznam zadevnih imen izdelkov je podan v Dodatku I. Znanstveni zaključki so na voljo v Dodatku II, dopolnjeni Povzetek glavnih značilnosti zdravila, označevanje in Navodilo za uporabo pa v Dodatku III.
English: The CHMP gave a positive opinion on 22 February 2007 recommending the harmonisation of the SPC, labelling and package leaflet for Xefo and associated names.
Slovenian: CHMP je dne 22. februarja 2007 podal pozitivno mnenje in priporočil uskladitev Povzetka glavnih značilnosti zdravila, označevanja in Navodila za uporabo za zdravilo Xefo in z njim povezana imena.
English: Further information on Atripla can be found on the Agency's website ema.europa.eu/en/medicines/human/EPAR/Atripla.
Slovenian: Nadaljnje informacije o zdravilu NexGard so na voljo na spletni strani agencije: ema.europa.eu/en/medicines/human/EPAR/Atripla.
English: • medicines that cause QT prolongation;
Slovenian: • zdravila, ki povzročajo podaljšanje intervala QT,
English: Other information about Atripla
Slovenian: Druge informacije o zdravilu Atripla
English: What measures are being taken to ensure the safe use of Atripla?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila Atripla?
English: In the European Union (EU), efavirenz has been approved since 1999, emtricitabine has been approved since 2003, and tenofovir disoproxil has been approved since 2002.
Slovenian: V Evropski uniji (EU) je efavirenz odobren od leta 1999, emtricitabin od leta 2003, dizoproksiltenofovirat pa od leta 2002.
English: Atripla received a marketing authorisation valid throughout the EU on 13 December 2007.
Slovenian: Za zdravilo Atripla je bilo 13. decembra 2007 izdano dovoljenje za promet, veljavno po vsej EU.
English: Patients should take the medicine regularly and not miss doses.
Slovenian: Bolniki morajo zdravilo jemati redno in odmerkov ne smejo izpuščati.
English: The Agency decided that Atripla's benefits are greater than its risks and recommended that it can be authorised for use in the EU.
Slovenian: Agencija je zaključila, da so koristi zdravila Atripla večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
English: Side effects reported with Atripla are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Atripla, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: As for all medicines, data on the use of Atripla are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Atripla stalno spremljajo.
English: An overview of Atripla and why it is authorised in the EU
Slovenian: Pregled zdravila Atripla in zakaj je odobreno v EU
English: Atripla (efavirenz / emtricitabine / tenofovir disoproxil)
Slovenian: Atripla (efavirenz/emtricitabin/dizoproksiltenofovirat)
English: What is Atripla and what is it used for?
Slovenian: Kaj je zdravilo Atripla in za kaj se uporablja?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Atripla have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Atripla upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Atripla keeps the amount of HIV in the blood at a low level.
Slovenian: Zdravilo Atripla ohranja nizko raven virusa HIV v krvi.
English: Why is Atripla authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Atripla odobreno v EU?
English: The European Medicines Agency noted that Atripla needs to be taken on an empty stomach to prevent certain side effects of one of its components, efavirenz.
Slovenian: Evropska agencija za zdravila je ugotovila, da je treba zdravilo Atripla jemati na prazen želodec, da se preprečijo določeni neželeni učinki ene od njegovih učinkovin, efavirenza.
English: Another study, which looked at how the combined tablet was absorbed in the body, showed that the combination tablet was absorbed in the same way as the separate medicines, when they were taken on an empty stomach.
Slovenian: Druga študija, v kateri so proučevali, kako se kombinirana tableta absorbira v telesu, je pokazala, da se je ta absorbirala enako kot ločena zdravila, kadar so bila vzeta na prazen želodec.
English: The main measure of effectiveness was the proportion of patients whose viral loads were below 200 copies/ml after 48 weeks.
Slovenian: Glavno merilo učinkovitosti je bil delež bolnikov, pri katerih je bilo virusno breme po 48 tednih manj kot 200 kopij/ml.
English: The company that markets Atripla will ensure that all doctors expected to prescribe the medicine are provided with an educational pack that includes information on the increased risk of kidney disease with medicines containing tenofovir disoproxil such as Atripla.
Slovenian: Družba, ki trži zdravilo Atripla, bo zagotovila, da bodo vsi zdravniki, ki naj bi predpisovali to zdravilo, prejeli izobraževalno gradivo, ki bo vsebovalo informacije o povečanem tveganju za nastanek ledvične bolezni pri zdravilih, ki vsebujejo dizoproksiltenofovirat, kot je na primer zdravilo Atripla.
English: What benefits of Atripla have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Atripla izkazalo v študijah?
English: • voriconazole (used to treat fungal infections).
Slovenian: • vorikonazol (ki se uporablja za zdravljenje glivičnih okužb).
English: It must not be used in patients in whom previous HIV treatment combinations have not worked or have stopped working.
Slovenian: Ne sme se uporabljati pri bolnikih, pri katerih predhodna kombinirana zdravljenja okužbe z virusom HIV bodisi niso bila učinkovita bodisi so prenehala biti učinkovita.
English: What are the risks associated with Atripla?
Slovenian: Kakšna tveganja so povezana z zdravilom Atripla?
English: The most common side effects with Atripla (which may affect more than 1 patient in 10) are dizziness, headache, diarrhoea, nausea (feeling sick), vomiting, rash, asthenia (weakness), hypophosphataemia (low blood levels of phosphates) and elevated levels of creatine kinase (an enzyme found in muscles).
Slovenian: Najpogostejši neželeni učinki zdravila Atripla (ki se lahko pojavijo pri več kot 1 bolniku od 10) so omotica, glavobol, driska, navzeja (siljenje na bruhanje), bruhanje, izpuščaj, astenija (šibkost), hipofosfatemija (nizka raven fosfatov v krvi) in zvišana raven kreatin kinaze (encima, prisotnega v mišicah).
English: For more information about using Atripla, see the package leaflet or contact a doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Atripla glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: After 48 weeks, 89% of the patients taking Atripla (181 out of 203) and 88% of those remaining on previous treatment (85 out of 97) had viral loads below 200 copies/ml.
Slovenian: Po 48 tednih je imelo virusno breme pod 200 kopij/ml 89 % (181 od 203) bolnikov, ki so jemali zdravilo Atripla, in 88 % (85 od 97) bolnikov, ki so nadaljevali prejšnje zdravljenje.
English: • certain medicines whose breakdown is blocked or accelerated by Atripla;
Slovenian: • določena zdravila, pri katerih zdravilo Atripla zavira ali pospešuje njihova okvara njihovo razgradnjo,
English: Because taking the medicine on an empty stomach could result in the component tenofovir being less effective, the Agency could not recommend Atripla for general use in patients with HIV and with high viral loads.
Slovenian: Ker bi ob jemanju zdravila na prazen želodec lahko postala učinkovina tenofovir manj učinkovita, agencija ni mogla priporočiti zdravilo Atripla za splošno uporabo pri bolnikih z okužbo z virusom HIV in visokim virusnim bremenom.
English: The main study of Atripla included 300 patients whose HIV infection was already being successfully treated with various combinations of antiviral medicines.
Slovenian: V glavno študijo z zdravilom Atripla so vključili 300 bolnikov, pri katerih so okužbo z virusom HIV že uspešno zdravili z različnimi kombinacijami protivirusnih zdravil.
English: It must also not be used in patients who have had arrhythmia (abnormal heartbeat) and patients with abnormal levels of electrolytes in the blood (for example, potassium or magnesium).
Slovenian: Ne sme uporabljati tudi pri bolnikih, ki imajo aritmijo (neenakomerno bitje srca), in bolnikih z nenormalno ravnijo elektrolitov v krvi (na primer kalija ali magnezija).
English: Atripla is an antiviral medicine used to treat adults infected with human immunodeficiency virus-1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Slovenian: Atripla je protivirusno zdravilo za zdravljenje odraslih bolnikov, ki so okuženi z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
English: It does not cure HIV infection or AIDS, but it holds off damage to the immune system and the development of infections and diseases associated with AIDS.
Slovenian: To zdravilo ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
English: The three active substances in Atripla are: efavirenz (600 mg), emtricitabine (200 mg) and tenofovir disoproxil (245 mg).
Slovenian: Učinkovine v zdravilu Atripla so: efavirenz (600 mg), emtricitabin (200 mg) in dizoproksiltenofovirat (245 mg).
English: It is only used in patients whose levels of HIV in the blood (viral loads) have been below 50 copies/ml for more than three months on their current HIV treatment combination.
Slovenian: Uporablja se samo pri bolnikih, pri katerih je raven virusa HIV v krvi (virusno breme) ob dosedanjem kombiniranem zdravljenju okužbe z virusom HIV že več kot tri mesece nižja od 50 kopij/ml.
English: Atripla contains three active substances: efavirenz, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI); emtricitabine, which is a nucleoside reverse transcriptase inhibitor; and tenofovir disoproxil, which is a ‘prodrug' of tenofovir, meaning that it is converted into the active substance tenofovir in the body.
Slovenian: Zdravilo Atripla vsebuje tri učinkovine: efavirenz, ki je nenukleozidni zaviralec reverzne transkriptaze (NNRTI), emtricitabin, ki je nukleozidni zaviralec reverzne transkriptaze, in dizoproksiltenofovirat, ki je predzdravilo tenofovirja, kar pomeni, da se v učinkovino tenofovir pretvori v telesu.
English: Atripla must not be used in patients with severe liver disease and patients with a family member who has had QT prolongation (an alteration of the electrical activity of the heart) or has died unexpectedly.
Slovenian: Zdravilo Atripla se ne sme uporabljati pri bolnikih, ki imajo hudo obolenje jeter, bolnikih, katerih bližnji sorodnik je imel podaljšan interval QT (spremenjeno električno dejavnost srca) ali je nenadoma umrl.
English: Atripla must not be started in patients with HIV that is resistant to any of the three active substances in Atripla.
Slovenian: Zdravilo Atripla se ne sme uvesti pri bolnikih z okužbo z virusom HIV, ki je odporen proti kateri koli od treh učinkovin v zdravilu.
English: All three active substances block the activity of reverse transcriptase, an enzyme produced by HIV that allows the virus to infect cells and make more viruses.
Slovenian: Vse tri učinkovine zavirajo delovanje reverzne transkriptaze, tj. encima, ki ga tvori virus HIV, da lahko okuži celice v telesu ter tvori nove viruse.
English: Atripla must also not be used in patients who are taking any of the following:
Slovenian: Prav tako se ne sme uporabljati pri bolnikih, ki uporabljajo karkoli od naslednjega:
English: Based on the data available it could only recommend Atripla as a convenient ‘once-a-day tablet' treatment for maintaining viral loads in patients whose viral loads have already been reduced with other HIV treatment.
Slovenian: Tako je lahko na podlagi razpoložljivih podatkov zdravilo Atripla priporočila le kot zdravljenje z eno tableto enkrat na dan za ohranjanje nizkega virusnega bremena pri bolnikih, ki so virusno breme že zmanjšali z drugimi zdravili proti okužbi z virusom HIV.
English: The study showed that switching to Atripla was as effective as remaining on the previous treatment combination.
Slovenian: Študija je pokazala, da je bil prehod na zdravilo Atripla enako učinkovit kot nadaljnje zdravljenje s prejšnjo kombinacijo zdravil.
English: See the package leaflet for further details and for the full list of restrictions.
Slovenian: Za več informacij oziroma za celoten seznam omejitev glejte navodilo za uporabo.
English: • St John's wort (a herbal preparation used to treat depression);
Slovenian: • šentjanževko (pripravek rastlinskega izvora za zdravljenje depresije),
English: Atripla can only be obtained with a prescription and treatment should be started by a doctor who has experience in the management of HIV infection.
Slovenian: Predpisovanje in izdaja zdravila Atripla je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
English: For the full list of side effects reported with Atripla, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Atripla, glejte navodilo za uporabo.
English: How is Atripla used?
Slovenian: Kako se zdravilo Atripla uporablja?
English: The study compared the effectiveness of switching to Atripla tablets with that of continuing the successful HIV treatment combination.
Slovenian: V študiji so učinkovitost prehoda na jemanje tablet zdravila Atripla primerjali z učinkovitostjo nadaljnjega zdravljenja z uspešno kombinacijo zdravil proti okužbi z virusom HIV.
English: The recommended dose of Atripla is one tablet once a day.
Slovenian: Priporočeni odmerek zdravila Atripla je ena tableta enkrat na dan. Priporočljivo je, da se jemlje na prazen želodec, po možnosti pred spanjem.
English: How does Atripla work?
Slovenian: Kako zdravilo Atripla deluje?
English: Trisenox has been authorised in the European Union since November 2016.
Slovenian: Zdravilo Trisenox je v EU odobreno od novembra 2016.
English: More information on Trisenox can be found on the Agency's website: ema.europa.eu/en/medicines/human/EPAR/trisenox
Slovenian: Dodatne informacije o zdravilu Trisenox so na voljo na spletni strani agencije: ema.europa.eu/en/medicines/human/EPAR/trisenox
English: A letter with this information will be sent to healthcare professionals.
Slovenian: Obvestilo se pošlje zdravstvenim delavcem.
English: Whereas underdosing may result in an inadequate effect overdose can result in serious and potentially fatal complications such as bleeding, severe infections and cardiac arrest.
Slovenian: Premajhen odmerek ima lahko neustrezen učinek, prevelik odmerek pa lahko povzroči resne zaplete z možnim smrtnim izidom, kot so krvavitve, hude okužbe in srčni zastoj.
English: Label of the immediate container
Slovenian: Oznaka na embalaži za takojšnjo porabo
English: Both should be diluted with 100-250 ml of either glucose 50 mg/ml (5%) solution for injection or sodium chloride 9 mg/ml (0.9%) solution for injection
Slovenian: Obe farmacevtski obliki zdravila je treba razredčiti s 100-250 ml raztopine glukoze 50 mg/ml (5 %) za injiciranje ali raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
English: The Agency is concerned that the coexistence of the two strengths may result in healthcare professionals inadvertently giving their patients too much (overdose) or not enough (underdose) of the active substance.
Slovenian: Agencija je zaskrbljena, da bi lahko zaradi sočasnega obstoja obeh jakosti zdravila zdravstveni delavci svojim bolnikom nehote dajali preveč (prevelik odmerek) ali premalo (premajhen odmerek) učinkovine.
English: Trisenox is a medicine used to treat adults with acute promyelocytic leukaemia (APL), a rare form of leukaemia (cancer of the white blood cells) caused by a genetic translocation (when there is a swap of genes between two chromosomes).
Slovenian: Zdravilo Trisenox se uporablja za zdravljenje odraslih z akutno promielocitno levkemijo (APL), tj. redko obliko levkemije (rak belih krvnih celic), ki jo povzroča genetska „translokacija“ (zamenjava genov med dvema kromosomoma).
English: EMA issues alert on the risk of dosing errors with the cancer medicine Trisenox
Slovenian: Agencija EMA opozarja na nevarnost napak pri odmerjanju zdravila za zdravljenje raka Trisenox
English: Front of the carton
Slovenian: Na sprednji strani embalaže
English: • To avoid any mix-ups while both presentations coexist, healthcare professionals must carefully check the concentration of the available presentation when calculating the volume of Trisenox to withdraw for dilution and infusion to ensure that the patient receives the correct dose of arsenic trioxide.
Slovenian: • Da bi se izognili zmešnjavi v času obstoja obeh farmacevtskih oblik zdravila, morajo zdravstveni delavci pri izračunu količine zdravila Trisenox skrbno preveriti koncentracijo razpoložljive farmacevtske oblike, ki jo uporabijo za redčenje in infuzijo, da bolniku zagotovijo pravilen odmerek arzenovega trioksida.
English: • To help differentiate between the two presentations, the packages have distinctive features shown below.
Slovenian: • Za lažje razlikovanje med oblikama zdravila so pakiranja razločno označena, kot je prikazano v nadaljevanju.
English: EMA is therefore alerting healthcare professionals using Trisenox of the risk of dosing errors and is reminding them to check the strength of the available presentation and follow the instructions for use carefully.
Slovenian: Agencija EMA zato zdravstvene delavce, ki uporabljajo zdravilo Trisenox, opozarja na nevarnost napak pri odmerjanju in priporoča, da preverijo jakost razpoložljive farmacevtske oblike in natančno upoštevajo navodila za uporabo.
English: Ampoule of 10 ml
Slovenian: Farmacevtska oblika ampula z 10 ml ampula s 6 ml
English: It is available as a concentrate that is made up into a solution for infusion (drip) into a vein, and contains the active ingredient arsenic trioxide.
Slovenian: Na voljo je v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije) v veno in vsebuje učinkovino arzenov trioksid.
English: Total content
Slovenian: Skupaj vsebnost
English: The new presentation will replace the existing one, which contains 1 mg/ml in each ampoule.
Slovenian: Nova farmacevtska oblika zdravila bo nadomestila sedanjo, ki vsebuje 1 mg/ml učinkovine na ampulo.
English: The European Medicines Agency (EMA) has recommended the approval of a new presentation of the injectable cancer medicine Trisenox (arsenic trioxide) that contains 2 mg/ml of the active substance in each vial.
Slovenian: Evropska agencija za zdravila (EMA) je priporočila, da se odobri nova farmacevtska oblika zdravila za injiciranje za zdravljenje raka Trisenox (arzenov trioksid), ki vsebuje 2 mg/ml učinkovine na ampulo.
English: • A new presentation of Trisenox (vial containing 2 mg/ml arsenic trioxide) will be introduced to replace the existing presentation (ampoule containing 1 mg/ml arsenic trioxide).
Slovenian: • Uvedena bo nova farmacevtska oblika zdravila Trisenox (ampula, ki vsebuje 2 mg/ml arzenovega trioksida), ki bo nadomestila sedanjo farmacevtsko obliko (ampula, ki vsebuje 1 mg/ml arzenovega trioksida).
English: In addition, the new vial contains a total volume of 6 ml (and a total content of 12 mg arsenic trioxide) whereas the existing ampoule contains 10 ml (and a total content of 10 mg).
Slovenian: Poleg tega nova ampula vsebuje skupno količino 6 ml (in skupno vsebnost arzenovega trioksida 12 mg), obstoječa pa skupno količino 10 ml (in skupno vsebnost arzenovega trioksida 10 mg).
English: Presentation
Slovenian: Dajanje
English: • Both formulations will coexist until stocks of the one containing 1 mg/ml have all been used.
Slovenian: • Dokler se ne porabi vsa zaloga ampul z 1 mg/ml, bosta v uporabi obe formulaciji zdravila.
English: Administration
Slovenian: Redčenje
English: After dilution Trisenox is given by an infusion (drip) into a vein over 1 to 2 hours.
Slovenian: Razredčeno zdravilo Trisenox se daje z eno- do dvournim infundiranjem (kapalno infuzijo) v veno.
English: The two strengths will temporarily coexist until the one containing 1 mg/ml has all been used.
Slovenian: Začasno, dokler se ne porabi vsa količina ampul z 1 mg/ml, bosta v uporabi obe jakosti zdravila.
English: Current presentation
Slovenian: Sedanja farmacevtska oblika
English: 117 Allée des Parcs 69800 Saint-Priest France
Slovenian: 117 Allée des Parcs 69 800 Saint-Priest Francija
English: 3 capsules a
Slovenian: 3 kapsule a
English: Paediatric population: Growth and development:
Slovenian: Pediatrična populacija: Rast in razvoj:
English: < 12 g/dL despite 4 weeks at reduced dose
Slovenian: < 12 g/dl kljub 4 tednom z zmanjšanim odmerkom
English: SVR% (n/N) 99% CI
Slovenian: SVR % (n/N) 99 % IZ
English: It is not known whether ribavirin is excreted in human milk.
Slovenian: Ni znano ali se ribavirin izloča v človeško mleko.
English: Volume of distribution is approximately 5,000 l. Ribavirin does not bind to plasma proteins.
Slovenian: Volumen porazdelitve je približno 5000 l. Ribavirin se ne veže na plazemske beljakovine.
English: Date of first authorisation: 10 June 2010 Date of latest renewal: 11 February 2015
Slovenian: DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja:10 Junij 2010 Datum zadnjega podaljšanja: 11 Februar 2015 DATUM ZADNJE REVIZIJE BESEDILA
English: Talk to your doctor if you or the child you are caring for:
Slovenian: Zdravniku povejte, če ste vi ali otrok za katerega skrbite:
English: Paediatric population No data are available in children below 3 years of age.
Slovenian: Pediatrična populacija Podatkov pri otrocih, mlajših od 3 let ni na voljo.
English: • Genotype 2 or 3: The recommended duration of treatment is 24 weeks.
Slovenian: • Genotip 2 ali 3: Priporočena dolžina zdravljenja je 24 tednov.
English: If the child/adolescent weighs (kg)
Slovenian: Če otrok ali mladostnik tehta (kg)
English: Your physician will prescribe the pack size which is best for you.
Slovenian: Vaš zdravnik bo določil velikost pakiranja, ki je za vas najbolj ustrezna.
English: • have HIV (human immunodeficiency virus) or have ever had any other problems with your immune system.
Slovenian: • imate HIV (virus humane imunske pomanjkljivosti) ali ste kadarkoli v preteklosti imeli težave z delovanjem vašega imunskega sistema.
English: By reporting side effects, you can also help provide more information on the safety of this medicine.
Slovenian: S tem, ko poročate o neželenih učinkih, lahko prispevate k zagotovitvi več informacij o varnosti tega zdravila.
English: Some children did not reach their projected height within 1-12 years after completing treatment.
Slovenian: Nekateri otroci tudi niso dosegli pričakovane telesne višine v obdobju 1 do 12 let po zaključku zdravljenja.
English: Another approximately 4% had a transient decrease below the lower limit of normal.
Slovenian: Pri nadaljnjih približno 4 % bolnikov je prišlo do prehodnega zmanjšanja vrednosti pod spodnjo mejo normale.
English: The clinical relevance of results from this single dose study is unknown.
Slovenian: Klinični pomen izsledkov te raziskave z enkratnim odmerkom ni znan.